Loading...

PETQ - PetIQ, Inc.

Analyst Downgrade Signal for 05-13-2022
Analyst Downgrade Signal: PETQ from Outperform to Perform by Oppenheimer
Price Target: $--



Stock Signal Information


Signal

Analyst Downgrade Stock
Report Date: 05-13-2022
Symbol: PETQ - PetIQ, Inc.
Sector: Healthcare
Industry: Drug Manufacturers—Specialty & Generic
Analyst Downgrade Signal: PETQ from Outperform to Perform by Oppenheimer
Price Target: $--

  PETQ Technical Chart

Company Contact

PetIQ, Inc. (PETQ)
923 S Bridgeway Pl
Eagle, IDAHO 83616
Phone: 12089398900
Website: http://www.petiq.com
CEO: Mr. McCord Christensen


Company Profile

PetIQ, Inc. operates as a pet medication and wellness company. It operates through two segments, Products and Services. The company offers prescription pet medications, including products for arthritis, thyroid, and diabetes and pain treatments, as well as heartworm preventatives, antibiotics, and other specialty medications; and over-the-counter medications and supplies, such as flea and tick control products in various forms comprising spot on treatments, chewables, and collars. It also provides health and wellness products that include dental treats and nutritional supplements, which comprise hip and joint, vitamins, and skin and coat products The company offers its products primarily under the PetIQ, PetArmor, VIP Petcare, VetIQ PetCare, VetIQ, Advecta, SENTRY, Sergeants, PetLock, Heart Shield Plus, TruProfen, Betsy Farms, PetAction, Minties, Vera, and Delightibles brands. In addition, the company offers a suite of services at community clinics and wellness centers hosted at pet retailers across 41 states, including diagnostic tests, vaccinations, prescription medications, microchipping, and wellness checks. As of March 10, 2020, it operated through approximately 60,000 points of distribution across retail and e-commerce channels. The company was founded in 2010 and is headquartered in Eagle, Idaho.